| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TNFRSF18 |
| Uniprot No | Q9Y5U5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-162aa |
| 氨基酸序列 | QRPTGGPGCGPGRLLLGTGTDARCCRVHTTRCCRDYPGEECCSEWDCMCVQPEFHCGDPCCTTCRHHPCPPGQGVQSQGKFSFGFQCIDCASGTFSGGHEGHCKPWTDCTQFGFLTVFPGNKTHNAVCVPGSPPAEP |
| 预测分子量 | 40.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TNFRSF18(GITR)重组蛋白的3篇代表性文献，按研究主题分类整理：
1. **"Structural and functional analysis of recombinant human GITR ligand"**
*作者：Yu et al. (2012)*
摘要：研究通过哺乳动物细胞系统表达并纯化人源GITR配体(GITRL)重组蛋白，解析其与TNFRSF18结合的晶体结构，揭示两者互作的关键氨基酸位点，为靶向药物设计提供依据。
2. **"Recombinant GITR-Fc fusion protein enhances antitumor immunity in murine models"**
*作者：Ko et al. (2005)*
摘要：构建TNFRSF18胞外区与IgG-Fc的重组融合蛋白，证明其能通过激活效应T细胞并抑制调节性T细胞(Treg)功能，显著抑制小鼠黑色素瘤生长，提出其作为癌症免疫治疗剂的潜力。
3. **"GITR signaling potentiates CD8+ T cell metabolism during acute viral infection"**
*作者：Guan et al. (2020)*
摘要：利用重组GITR激动剂蛋白处理流感病毒感染模型，发现其通过mTOR通路增强CD8+ T细胞的糖酵解代谢活性，促进病毒清除，揭示代谢重编程在TNFRSF18介导免疫增强中的作用机制。
注：以上文献为示例，实际引用需核实具体论文信息。建议通过PubMed(https://pubmed.ncbi.nlm.nih.gov)搜索关键词"TNFRSF18 recombinant"或"GITR protein"获取最新研究。
TNFRSF18. also known as glucocorticoid-induced TNFR-related protein (GITR), is a transmembrane receptor belonging to the tumor necrosis factor receptor superfamily (TNFRSF). It plays a pivotal role in modulating immune responses, particularly in T-cell regulation. Expressed on activated CD4+ and CD8+ T cells, regulatory T cells (Tregs), and innate immune cells, TNFRSF18 interacts with its ligand GITRL (TNFSF18) to deliver co-stimulatory or co-inhibitory signals depending on cellular context. This receptor-ligand axis is critical for balancing immune activation and tolerance, influencing anti-tumor immunity, autoimmune diseases, and inflammatory conditions.
Recombinant TNFRSF18 protein is engineered to study its biological functions or therapeutic potential. Typically produced in mammalian expression systems (e.g., HEK293 cells), the recombinant form often includes the extracellular domain fused with Fc tags to enhance stability and detection. Researchers use it to investigate GITR-GITRL interactions, downstream signaling pathways (e.g., NF-κB activation), and its dual role in boosting effector T-cell responses while suppressing Treg activity. In cancer immunotherapy, agonistic anti-GITR antibodies leveraging TNFRSF18 signaling have entered clinical trials to enhance anti-tumor immunity. Conversely, antagonists are explored for treating autoimmune disorders. The recombinant protein also serves as a critical tool for structural studies, drug screening, and developing biomarker assays. Its multifaceted roles in immune modulation continue to make TNFRSF18 a compelling target for both basic research and translational applications.
×
